← Back to Home

FDA Requires GLP-1 Drugs to Add Warning About Rare Optic Neuropathy; Causal Link Remains Unclear

An analysis of trials involving more than 130,000 people found a slightly higher incidence of a rare optic neuropathy among GLP-1 users. Although the absolute risk is low, the potential for permanent vision damage prompted the FDA to require updated warnings across the drug class.

By SURL BioNews

As blood glucose-lowering and weight-loss drugs become part of long-term treatment, very rare side effects that may cause permanent harm also shape discussions between patients and clinicians about medication use. On November 9, the U.S. Food and Drug Administration (FDA) announced that it would require all GLP-1 receptor agonists to add the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION) to the “Warnings and Precautions” section of their prescribing information.

The condition involves reduced blood flow to the front of the optic nerve and may cause sudden, painless vision loss in one eye, potentially leading to permanent blindness. The update covers products including Ozempic and Wegovy, as well as Mounjaro and Zepbound, which act on both GIP and GLP-1 receptors. ABC News noted that Soliqua, a combination product containing a GLP-1 drug ingredient, is also included; BioSpace reported that the FDA announcement lists 12 drugs.

The safety signal emerged from an FDA pooled analysis of 126 randomized controlled trials involving 134,253 patients. The analysis identified 15 probable NAION events, with 10 occurring in the GLP-1 treatment groups and another 5 in the placebo groups. Adjusted for follow-up time, the rate was 6.4 cases per 100,000 person-years in the GLP-1 groups, compared with 3.8 cases in the combined control groups receiving placebo or other blood glucose-lowering drugs. “Person-years” combines the number of participants with the duration of follow-up; it does not represent the probability of developing the condition after a single dose.

These figures show that the events are rare, while also leaving limitations on their interpretation: with only 15 cases overall, this pooled analysis alone cannot establish the individual risk of each drug. The FDA is updating warnings across the drug class to alert healthcare professionals to potential harm; the available data remain insufficient to treat the observed difference as an established causal relationship.

Results have also varied across studies. BioSpace’s summary of the FDA’s retrospective studies noted that, among adults with type 2 diabetes receiving drug treatment, GLP-1 drugs did not show a higher risk of NAION than SGLT-2 inhibitors; however, an increased risk was observed compared with DPP-4 inhibitors. The findings changed depending on the comparator, making this safety signal more complex to interpret.

Another challenge in clarifying the cause is patients’ underlying health conditions. NAION risk factors such as diabetes, hypertension, and sleep apnea are also common among people taking GLP-1 drugs. The FDA said this overlap makes postmarketing adverse event reports difficult to interpret; a review of animal data has also yet to identify a mechanism that could explain how the drugs might increase the risk.

For people receiving treatment, the warning’s most immediate significance is recognizing symptoms and seeking help promptly. The FDA recommends contacting a healthcare professional immediately if sudden vision loss, blurred vision, or blind spots occur; suspected cases should be referred promptly for an ophthalmic evaluation. Patients who have developed NAION should discuss with their physician whether to continue treatment, making an individualized decision based on treatment benefits and risks to vision.

References

  1. FDA
  2. ABC News
  3. BioSpace